aiom.it


aiom.it Website Info

aiom.it (AIOM IT specializes in providing comprehensive IT solutions and managed services tailored to meet the needs of businesses seeking efficient and innovative technology support. Their expertise includes cloud computing, network management, cybersecurity, and digital transformation strategies to enhance operational performance and security.) was registered first at 2009-09-28 11:01:09. It's hosted by Eventi Telematici. DNS looks Active and website looks Accessable. According to Google, website speed score is 24/100 and AVERAGE. Website looks safe for children.
aiom.it


aiom.it Website Tags

Domain Status:
✓ Active
Is Site Accessable?:
✓ Yes
SSL(https):
✓ Yes
Accessable Url:
Title:
AIOM | Associazione Italiana di Oncologia Medica – Official Website
Description:
AIOM IT offers innovative IT solutions, managed services, and consultancy to help businesses optimize their technology infrastructure and drive digital transformation.
Mobile Friendly?:
✓ Yes
Canonical URL:
[Not Set]

aiom.it Domain & Whois Details

Refresh
Domain Create Date:
2009-09-28 11:01:09
Domain Age:
15 years, 9 months, 4 days
Domain Expire Date:
2014-11-13
Domain Last Update Date:
2014-11-13
Domain Owner:
AIOM - Associazione Italiana di Oncologia MedicaCascinu StefanoTechnical SupportREGISTER-REG
Server Type:
Apache
Hosting Location:
SE - SWEDEN
Hosting Provider:
Eventi Telematici
IP:
193.235.43.63



aiom.it Website Speed (Desktop)

Refresh
Overall Category:
AVERAGE
The human readable speed "category"
Speed Index:
24
Speed Index shows how quickly the contents of a page are visibly populated. [Learn more about the Speed Index metric].
Cumulative Layout Shift (CLS):
0.18 (AVERAGE)
The Cumulative Layout Shift (CLS) metric measures how much unexpected layout shifts affect the user experience on a page. These layout shifts occur when content moves around without prior user input. CLS
Time to First Byte (TTFB):
0.77 s (FAST)
TTFB (time to first byte) is the number of milliseconds it takes for a client’s browser to receive the first byte of the response from the web server. Usually, TTFB can be improved with faster hosting and server optimizations. TTFB
First Input Delay (FID):
3 ms (FAST)
First Input Delay (FID) measures the time from when the user interacts with your site for the first time (click a link, tap on a button, etc.) to the time when the browser is able to respond to that interaction. Google recommends keeping FID below 100ms for a good user experience. FID
First Contentful Paint (FCP):
1.212 s (FAST)
FCP (First Contentful Paint) measures the time from a user’s navigation to when the browser renders the first bit of content from the DOM. In other words, FCP marks the time at which the first text or image is painted for the user. According to PageSpeed Insights, FCP should occur in under 2 seconds. FCP
Interaction to Next Paint (INP):
38 ms (FAST)
Interaction to Next Paint (INP) is a web performance metric that measures user interface responsiveness – how quickly a website responds to user interactions like clicks or key presses. Specifically, it measures how much time elapses between a user interaction like a click or key press and the next time the user sees a visual update on the page. INP
Largest Contentful Paint (LCP):
2.538 s (AVERAGE)
Largest Contentful Paint (LCP) is a metric that measures when the largest content in the viewport is rendered. It is used to measure how long it takes for the main content of your webpage to appear on the screen. Everything below 2.5s is considered good LCP time by PageSpeed Insights. LCP
Total Size:
4344 KB
Total Size. Large network payloads cost users real money and are highly correlated with long load times.
Server Response Time:
1899 ms
Initial server response time. Keep the server response time for the main document short because all other requests depend on it. [Learn more about the Time to First Byte metric](https://developer.chrome.com/docs/lighthouse/performance/time-to-first-byte/).
Final Url:
https://www.aiom.it/
Canonicalized and final URL for the document, after following page redirects (if any).
Last Date Checked:
6/17/2023 7:51:39 AM
The last time we checked this website.

aiom.it HTML Resources

Type
Request Count
Size
Total
185
4,344 KB
Image
78
3,719 KB
Third-party
83
246 KB
Script
3
234 KB
Font
4
209 KB
Other
78
79 KB
Stylesheet
21
76 KB
Document
1
25 KB
Media
0
0 KB

aiom.it Website Safety

Refresh
Last Check Date:
2/21/2023 4:47:23 PM
Fortiguard:
Health and Wellness
Mcafee Category:
Health
OpenDNS:
notdecidedyet
Cloudflare DNS:
OK
MyWot Child Safety:
99

aiom.it HTTP Headers

Refresh
Cache-Control :
max-age=172800
Connection :
Upgrade, Keep-Alive
Content-Type :
text/html; charset=UTF-8
Date :
Wed, 07 Jun 2023 12:42:13 GMT
expires :
Fri, 09 Jun 2023 12:42:13 GMT
Keep-Alive :
timeout=1, max=100
Link :
<https://www.aiom.it/wp-json/>; rel="https://api.w.org/", <https://www.aiom.it/wp-json/wp/v2/pages/2
Server :
Apache
Transfer-Encoding :
chunked
Upgrade :
h2,h2c
Vary :
Accept-Encoding,User-Agent


aiom.it W3C HTML Validation Check Now

Last Check Date:
5/28/2023 12:00:00 AM
Errors:
124
Warnings:
0
Info:
22

aiom.it Similar Sites

Website
Title
Rank
Sprint Systems - Innovative IT and Technology Solutions
Top Digital Marketing Agency in Hyderabad - Digital Marketing Company
4,801,119
Gi Group agenzia per il lavoro, offerte temporary e permanent.
4,011,664
Olympia - Expert in Digital Transformation and IT Solutions
2,928,408
AI Services & Capabilities | Transform Your Business with AI Innovation
1,222,227

aiom.it Site Keywords

Associazione Italiana di Oncologia Medica
Cancro
clinical trials
Cura tumori
digital transformation
IT consultancy
IT SOLUTIONS
managed services
Oncologi
Oncologia medica
prevenzione tumori
ricerca clinica
ricerca sperimentale
technology services
Tumore

aiom.it Site H Tags

Check Now
h2
Raccomandazioni sull’uso della vaccinazione anti...
h2
Raccomandazioni AIOM per l’implementazione...
h2
Raccomandazioni AIOM sull’uso della vaccinazione...
h2
Annuario dei Centri di Ricerca Oncologica in Italia
h2
Libro Bianco 2022 – XII edizione
h2
RUOLO DELL’ONCOLOGO, profilo delle competenze e...
h2
BANDO DI SELEZIONE PROGETTI DI RICERCA 2023: Bevacizumab nella terapia dei tumori solidi in fase ava
h2
Tumori: l’obesità riduce l’efficacia dell’immunoncologia. Nei pazienti diabetici peggiora la sopravv
h2
AIOM: “PLAUDIAMO AL BANDO AIFA PER LA RICERCA CLINICA INDIPENDENTE SERVONO STUDI DI SEQUENZA TERAPEU
h2
NEOPLASIADONNA – Tumori femminili e attenzione alla salute
h2
TUMORI: “QUASI IL 70% DEGLI STUDI ANALIZZA LA QUALITÀ DI VITA. FONDAMENTALI I SINTOMI RIPORTATI DAI
h2
TUMORI: “SONO 149 I CENTRI DI RICERCA IN ITALIA, PIÙ DELLA METÀ AL NORD. I NOSTRI STUDI ALL’AVANGUAR
h2
TUMORE DELLA PROSTATA, NEL 2022 40.500 DIAGNOSI. +16% IN CINQUE ANNI. AIOM: DALL’INTELLIGENZA ARTIFI
h2
TUMORE DEL COLON-RETTO, 48.100 CASI IN ITALIA NEL 2022. + 4.400 IN 2 ANNI. AIOM: “7 SU 10 NON ADERIS
h2
Olaparib non rimborsabile nel carcinoma del pancreas
h2
Linee di indirizzo sull’attività fisica: Accordo Stato...
h2
Programmi Expanded Access attivi in Italia
h2
CTS AIFA nega inserimento di pembrolizumab e dell’associazione nivolumab + ipilimumab nelle liste 64
h2
Comunicazione EMA sui medicinali contenenti fluorouracile, capecitabina, tegafur e flucitosina
h2
COVID19: misure transitorie relative alla proroga dei piani terapeutici AIFA
h2
Pubblicata sulla Gazzetta Ufficiale l’autorizzazione all’utilizzo del regorafenib in pazienti con re
h2
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patient
h2
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
h2
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Pati
h2
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
h2
Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice fro
h2
2023 Cancer Research: from Orlando to Palermo
h2
ONCOGENETICA: nuove implicazioni cliniche, aspetti psicologici e bioetici
h2
La complessità nelle terapie di supporto in oncologia e nelle cure palliative: guardando oltre l’Ori
h2
From San Antonio to Rome 2022
h2
News in GI Oncology 2023
h2
AIOM con i medici in formazione
h3
News dalle Istituzioni
h3
RACCOMANDAZIONI
h3
Ricerca argomenti per TAG
h3
Aggiornamento Scientifico per gli Oncologi
h3
FOCUS: relazioni disponibili
h3
Comunicati Stampa AIOM
h3
PUBBLICAZIONI
h4
Gli eventi AIOM
h4
Ricerca per Categoria
h4
AIOM – Associazione Italiana di Oncologia Medica
h4
Sede
h4
Seguici sui social network

aiom.it Sites with Same Names

Website
Title
Rank
All In One Marketing - AIOM - Your Virtual Marketing Department
32,211,413
Home : The Association of Inbound Operators (Mauritius) AIOM - The Association of Inbound Operators (Mauritius) AIOM
31,354,822
AIOM - Associazione di Ingegneria Off-Shore e Marina

What is SitesDB?

SitesDB is one of the largest databases of websites and domain names on the internet, with over 40 million entries and growing. For more than 12 years, we've been manually verifying and updating website and domain details, combining human expertise with AI-powered systems to ensure the accuracy and relevance of our data.

At SitesDB, we provide in-depth technical and useful information about websites and domains, including:

  • Website meta tags
  • Domain & WHOIS data
  • General backlink and ranking statistics
  • Social media engagement stats
  • Root page speed insights
  • Website content and HTML resources
  • Website safety and security details, sourced from multiple trusted security providers
  • HTTP headers analysis
  • HTML validation reports
  • Lists of similar websites and competitors
  • Website keyword analysis, including top traffic-driving keywords
  • Heading structure (H tags) breakdown
  • Domain variations across different TLDs (Top-Level Domains)

In addition to this data, SitesDB offers a suite of website analysis tools — including Chrome CRUX, Google Lighthouse, and our own AI-enhanced algorithms — to help identify alternative websites, direct competitors, and similar sites, all continuously refined through both automated systems and human review.